IPSEY has been the topic of several other research reports. Royal Bank of Canada boosted their price target on Ipsen from €107.00 ($109.18) to €108.00 ($110.20) in a research note on Monday, October 31st. Cheuvreux upgraded Ipsen from a hold rating to a buy rating and set a €110.00 ($112.24) target price on the stock in a research note on Friday, August 26th. Morgan Stanley upped their target price on Ipsen from €84.00 ($85.71) to €86.00 ($87.76) and gave the stock an underweight rating in a research note on Thursday, October 13th. UBS Group upped their target price on Ipsen from €102.00 ($104.08) to €107.00 ($109.18) in a research note on Friday, November 4th. Finally, Berenberg Bank upped their target price on Ipsen from €98.00 ($100.00) to €102.00 ($104.08) and gave the stock a hold rating in a research note on Tuesday, August 2nd. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Ipsen presently has a consensus rating of Hold and an average target price of $107.22.
Ipsen Stock Performance
Ipsen stock opened at $25.99 on Monday. The business’s 50-day simple moving average is $24.85 and its two-hundred day simple moving average is $24.39. Ipsen has a fifty-two week low of $21.17 and a fifty-two week high of $32.51.
Ipsen Company Profile
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents.
- Get a free copy of the StockNews.com research report on Ipsen (IPSEY)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.